New registry tracks rezdiffra safety in pregnant NASH patients

NCT ID NCT07541469

NEW Recruiting now Knowledge-focused Sponsor: Madrigal Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen May 01, 2026 · Last updated May 01, 2026

Summary

This study is a registry that collects information on the safety of Rezdiffra (resmetirom) in women with NASH who took the drug during pregnancy or while breastfeeding, and their infants up to 12 months old. It does not give any treatment or change care—it simply observes and records pregnancy outcomes, birth defects, and baby growth and development. The goal is to better understand any risks, helping doctors and patients make informed decisions.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Madrigal Pharmaceuticals
RECRUITING

West Conshohocken, Pennsylvania, 19428, United States

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

MASH - METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS